Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/16/18
End: 06/21/24
Due: 06/21/25
Phase: N/A
Priority: Normal
Start: 11/18/20
End: 03/01/26
Due: 03/01/27
Phase: N/A
Priority: Normal
Start: 09/23/19
End: 07/16/24
Due: 07/16/25
Phase: N/A
Priority: Normal
Start: 12/14/20
End: 05/31/25
Due: 05/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | NCT03440437 | invoX Pharma Limited | user2@example.com | None | 2018-04-16 | 2024-06-21 | 2025-06-21 | - | - | 2025-07-14 |
| FS120 Phase 1/1b Study in Patients With Advanced Malignancies | NCT04648202 | invoX Pharma Limited | user2@example.com | None | 2020-11-18 | 2026-03-01 | 2027-03-01 | - | - | 2025-07-14 |
| Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | NCT04096638 | invoX Pharma Limited | user2@example.com | None | 2019-09-23 | 2024-07-16 | 2025-07-16 | - | - | 2025-07-14 |
| FS222 First in Human Study in Patients With Advanced Malignancies | NCT04740424 | invoX Pharma Limited | user2@example.com | None | 2020-12-14 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |